Global Blood Therapeutics


Global Blood Therapeutics Reports Q1 Beat, Impressive Oxbryta Sales

Global Blood Therapeutics (GBT) has reported a solid first quarter earnings beat, with Q1 GAAP EPS of -$1.20 beating the Street forecast by $0.

3 Biotech Stocks That Could Explode Higher in 2019

Black Friday is past. So is Cyber Monday.

Global Blood Therapeutics (GBT) Gets Attention of FDA As Well As Investors

Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …

Global Blood Therapeutics (GBT): Now That’s a Go Ahead!

On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock …

Top Analyst Shines Light on Global Blood Therapeutic (GBT) Following Phase 2a Results in SCD

Global Blood Therapeutics (NASDAQ:GBT) investors got cold feet today, sending shares tumbling nearly 17%. The reason?

Global Blood Therapeutics Inc (GBT): Breakthrough Designation for Lead Asset Has This Top Analyst Hopeful on Voxelotor’s Prospects

One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.

Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT)

Pain Therapeutics to try again with REMOXY NDA Investors love biotech stocks for the lottery ticket-like returns they can offer if a company …

2 Pharmaceutical Stocks That Can Double in a Year: Global Blood Therapeutics Inc (GBT), TherapeuticsMD Inc (TXMD)

These two pharma stocks all have upside of over 100% say top Wall Street analysts.

Cowen Boosts Price Target on Global Blood Therapeutics (GBT) Amid GBT-440 Phase III HOPE Trial FDA-Accepted Design

Today, Global Blood Therapeutics Inc (NASDAQ:GBT) announced design of the pivotal two-part GBT-440 Phase III HOPE trial in evaluating adults and adolescents with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts